340179-89-7

Usage

Uses

Used in Organic Synthesis:
C-(1-TRITYL-1H-IMIDAZOL-4-YL)-METHYLAMINE is used as a protecting group in organic synthesis for [application reason]. The trityl group's sensitivity to acidic and basic conditions makes it a valuable tool in the synthesis of complex organic molecules, where selective protection and deprotection of functional groups are necessary.
Used in Drug Development:
In the pharmaceutical industry, C-(1-TRITYL-1H-IMIDAZOL-4-YL)-METHYLAMINE is used as a building block or intermediate in the development of new drugs for [application reason]. Its unique structure and reactivity may contribute to the creation of novel therapeutic agents with specific biological activities.
Used in Medicinal Chemistry:
C-(1-TRITYL-1H-IMIDAZOL-4-YL)-METHYLAMINE is utilized in medicinal chemistry as a potential candidate for the design of new pharmaceuticals for [application reason]. Its imidazole core and trityl substituent may offer unique opportunities for the modulation of biological targets, leading to the discovery of new drugs with improved efficacy and selectivity.

InChI:InChI=1/C23H21N3/c24-16-22-17-26(18-25-22)23(19-10-4-1-5-11-19,20-12-6-2-7-13-20)21-14-8-3-9-15-21/h1-15,17-18H,16,24H2

Upstream product

• 312937-01-2 2,2,2-trifluoro-N-(2-(1-trityl-1H-imidazol-4-yl)ethyl)acetamide 
• 76-83-5 trityl chloride 

Relevant academic research and scientific papers

DOUBLE-ACYLATED GLP-1 DERIVATIVES

The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 37 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at a position corresponding to position 26 of GLP-1 (7-37), and a maximum of ten amino acid modifications as compared to GLP-1 (7-37), wherein the first K residue is designated K37, and the second K residue is designated K26, which derivative comprises two albumin binding moieties attached to K26 and K37, respectively, wherein the albumin binding moiety comprises a protracting moiety selected from: ????????Chem. 1:?????HOOC-(CH2)x-CO-* ????????Chem. 2:?????HOOC-C6H4-O-(CH2)y-CO-* ????????Chem. 3:?????R1-C6H4-(CH2)z-CO-* ????????Chem. 4:?????HOOC-C4SH2-(CH2)w-CO-* in which x is an integer in the range of 6-18, y is an integer in the range of 3-17, z is an integer in the range of 1-5, R1 is a group having a molar mass not higher than 150 Da, and w is an integer in the range of 6-18; with the proviso that when the protracting moiety is Chem. 1, the albumin binding moiety further comprises a linker of formula Chem. 5: *-NH-(CH2)2-(O-(CH2)2)k-O-(CH2)n-CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical use thereof, for example in the treatment and/or prevention of all forms of diabetes and related diseases, as well as to corresponding novel peptides and side chain intermediates. The derivatives are suitable for oral administration.